Zellweger Syndrome Knockout Mouse Models Challenge Putative Peroxisomal β-Oxidation Involvement in Docosahexaenoic Acid (22:6n-3) Biosynthesis
- 31 January 2001
- journal article
- review article
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 72 (1) , 1-7
- https://doi.org/10.1006/mgme.2000.3101
Abstract
No abstract availableKeywords
This publication has 41 references indexed in Scilit:
- Genotype–Phenotype Correlations in Disorders of Peroxisome BiogenesisMolecular Genetics and Metabolism, 1999
- Peroxisomal Disorders: Genotype, Phenotype, Major Neuropathologic Lesions, and PathogenesisBrain Pathology, 1998
- On the molecular etiology of decreased arachidonic (20:4n-6), docosapentaenoic (22:5n-6) and docosahexaenoic (22:6n-3) acids in Zellweger syndrome and other peroxisomal disordersMolecular and Cellular Biochemistry, 1997
- Peroxisomal Disorders: OverviewAnnals of the New York Academy of Sciences, 1996
- Fatty acid composition of late embryonic and early postnatal rat brainLipids, 1996
- Polyunsaturated fatty acids in the developing human brain, erythrocytes and plasma in peroxisomal disease: therapeutic implicationsJournal of Inherited Metabolic Disease, 1995
- Abnormal profiles of polyunsaturated fatty acids in the brain, liver, kidney and retina of patients with peroxisomal disordersBrain Research, 1992
- Fatty acid composition of brain phospholipids in aging and in Alzheimer’s diseaseLipids, 1991
- The Cerebrohepatorenal (Zellweger) SyndromeNew England Journal of Medicine, 1984
- Peroxisomal and Mitochondrial Defects in the Cerebro-Hepato-Renal SyndromeScience, 1973